FDA Review of Varenicline and Risk of Cardiovascular Adverse Events

Published Online: Wednesday, December 19, 2012
Follow Pharmacy_Times:
This podcast, from the Centers for Disease Control and Prevention, discusses a drug safety communication released by the FDA on December 12, 2012, regarding the risk of cardiovascular adverse events associated with the smoking-cessation drug varenicline (Chantix).
 
To download the podcast, click here.
Related Articles
In light of misrepresented statistics and overstated fears about statin-related adverse events, here are 3 of the biggest myths your patients may have heard about these life-saving medications—and the facts
Taking an antidepressant used in smoking cessation for an extended period of time prior to quitting may help smokers achieve their goal.
Labels of prescription testosterone products must now include information about possible cardiovascular and stroke risks associated with their use.
Casting doubt on previous conjectures, a new study suggests that statins do not protect patients against Parkinson’s disease.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$